Surmodics Inc SRDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRDX is a good fit for your portfolio.
News
-
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
-
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
-
Surmodics to Participate in Upcoming Investor Conferences in March and April
-
Surmodics Shares Up 8% on FDA Approval for SurVeil Drug-Coated Balloon
-
Surmodics Gets FDA Approval for SurVeil Drug-Coated Balloon
-
Surmodics Receives FDA Clearance for Thrombectomy System
Trading Information
- Previous Close Price
- $33.33
- Day Range
- $32.89–35.50
- 52-Week Range
- $16.79–39.41
- Bid/Ask
- $33.53 / $40.72
- Market Cap
- $491.85 Mil
- Volume/Avg
- 380,999 / 67,452
Key Statistics
- Price/Earnings (Normalized)
- 51.28
- Price/Sales
- 3.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 376
- Website
- https://www.surmodics.com
Comparables
Valuation
|
Metric
|
SRDX
|
301060
|
688067
|
|---|---|---|---|
Price/Earnings (Normalized) | 51.28 | 31.53 | 43.70 |
Price/Book Value | 3.88 | 2.30 | 2.29 |
Price/Sales | 3.39 | 2.40 | 5.45 |
Price/Cash Flow | 21.50 | 9.13 | 48.02 |
Price/Earnings
SRDX
301060
688067
Financial Strength
|
Metric
|
SRDX
|
301060
|
688067
|
|---|---|---|---|
Quick Ratio | 3.75 | 2.50 | 0.80 |
Current Ratio | 4.84 | 3.03 | 6.63 |
Interest Coverage | 3.75 | −18.88 | — |
Quick Ratio
SRDX
301060
688067
Profitability
|
Metric
|
SRDX
|
301060
|
688067
|
|---|---|---|---|
Return on Assets (Normalized) | 5.17% | −5.18% | 4.73% |
Return on Equity (Normalized) | 8.16% | −8.53% | 5.32% |
Return on Invested Capital (Normalized) | 8.20% | −6.57% | 5.24% |
Return on Assets
SRDX
301060
688067
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Cgxmgsv | Mrbmt | $184.4 Bil | |
SYK
| Stryker Corp | Fswcfrqfsd | Mbfd | $125.0 Bil | |
MDT
| Medtronic PLC | Vwmcmhzss | Rzhkjm | $107.4 Bil | |
BSX
| Boston Scientific Corp | Vcyzlswts | Nkbyy | $106.2 Bil | |
EW
| Edwards Lifesciences Corp | Lddxzcpgpj | Lnlzb | $50.8 Bil | |
DXCM
| DexCom Inc | Yjlnsyvkgd | Pzwmv | $49.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Vmjvswwgr | Rmg | $24.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Glthbzqr | Vkqwgw | $24.4 Bil | |
ALGN
| Align Technology Inc | Qqnqgqj | Mcvmn | $21.4 Bil | |
PODD
| Insulet Corp | Znyljjpxk | Zfkwhd | $11.9 Bil |